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Toxicologic studies with culture material of
Fusarium verticillioides (= F. moniliforme)
grown on corn have been performed in a vari-
ety of experimental animals, including pigs,
sheep, horses, baboons, and rats (1). The sci-
entiﬁc importance of this fungal species, how-
ever, was first recognized with the finding
that contamination of feedstuff, particularly
corn, with F. verticillioides was responsible for
natural outbreaks of the mycotoxicosis equine
leukoencephalomalacia (ELEM) (2,3). This
implied that the causative principle(s)
occur(s) under natural conditions and could
affect the health of livestock and also humans.
The latter was of particular interest because
many human populations in southern Africa
consume corn as the major dietary staple (4).
Efforts were launched in South Africa and
elsewhere to develop sensitive screening
methods to aid in the chemical isolation of
the active compound(s). A duckling toxicity
assay was designed whereby numerous isolates
of the F. verticillioides were screened for the
presence of toxic secondary metabolites pro-
duced by the fungus (5). Several isolates with
different degrees of duckling toxicity were
identiﬁed and formed the basis of further tox-
icologic studies in various animal species.
One of these, designated F. verticillioides strain
MRC 826, was identiﬁed as one of the most
toxic isolates from corn. This strain caused
many toxic effects in experimental animals,
such as ELEM in horses, pulmonary edema in
pigs, acute nephrosis and hepatosis in sheep,
and cirrhosis, intraventricular cardiac throm-
bosis, and nephrosis in rats (1). A less toxic
strain, F. verticillioides MRC 602, also induced
acute congested heart failure in baboons. A
remarkable ﬁnding of these early experiments
was that the main target organ differed in each
animal species although certain organs, includ-
ing the liver and kidneys, were consistently
affected. It was suggested that rats provided the
best screening system able to mimic biologic
effects of the fungus in the various mammalian
species (5). Toxicologic studies in rats eventu-
ally formed the basis for evaluating the car-
cinogenic effects of the potent mutagen fusarin
C and subsequently for isolating the fumonisin
(F)B mycotoxins from culture material of
F. verticillioides MRC 826 (6,7). 
Studies in nonhuman primates were
initially performed with baboons (1). A
prominent lesion was acute congestive heart
failure, and liver cirrhosis was observed as a
principal lesion in another baboon. The latter
study was performed between 5 months and
2 years at varying dietary levels of the culture
material of F. verticillioides strain MRC 602.
Subsequent studies were conducted in rats to
evaluate the long-term toxicologic effects of
different isolates of F. verticillioides including
strain MRC 826 (8,9). At the same time, a
long-term toxicity study was initiated at the
Programme on Mycotoxins and Experimental
Carcinogenesis (PROMEC), Medical
Research Council (MRC), Tygerberg, South
Africa, in vervet monkeys (10,11) by feeding
different dietary levels of F. verticillioides
strain MRC 826. In this article we describe
the clinical and biochemical data and
dose–response effects in relation to the FB
exposure levels during the course of the
experiment (approximately 13.5 years).
Materials and Methods
Animals and Diets
Twelve vervet monkeys (Cercopithecus
aethiops), consisting of eight females and four
males weighing between 1 and 2 kg, were
selected from the breeding colony of the
MRC Primate Unit of the Experimental
Biology Programme of the Medical Research
Council, Tygerberg, South Africa. They were
caged singly in a closed environment (26 ±
1°C) with a 12-hr photoperiod, 50% humid-
ity, and 20 air changes/hr. The vervet mon-
keys were divided into three groups consisting
of six animals (four females and two males) in
the high-dose group, four animals (two males
and two females) in the low-dose group, and
two animals (females) in the control group.
The diet consisted of 57 g of commercial pre-
cooked corn meal, 1 g of an in-house vitamin
mixture, and 10 g of a protein–vitamin–
mineral supplement (PVM Product, Pretoria,
South Africa). Culture material of F. verticil-
lioides MRC 826 was incorporated at different
We conducted a chronic feeding study in vervet monkeys (Cercopithecus aethiops) over 13.5 years.
The experimental design consisted of two dietary treatment groups, each including males and
females, fed varying levels of culture material of Fusarium verticillioides (Sacc.) Nirenberg (= F.
moniliforme Sheldon) strain MRC 826 mixed into their daily food ration. Two females were included
as treatment controls. We conducted blood chemical analyses bimonthly and recorded all clinical
signs during the course of the experiment. We took liver biopsies at various stages during the initial
phase of the experiment. Several monkeys were terminated in extremis during the experiment.
Detailed feed intake profiles were determined 5 years after the experiment began, and the
fumonisin B (FB) mycotoxin content of the feed was determined during the ﬁnal stages of the
experiment. The apparent FB consumption patterns were related to changes observed in the
biochemical parameters in the blood and urine, including the liver function enzymes and creatinine
clearance as well as differential blood counts and sphingolipid levels in the serum and urine. An
apparent no-effect threshold for kidney and liver damage is estimated to be between 0.11 and 0.18
mg FB/kg body weight (bw)/day, which corresponds to a feed contamination level of between 8.21
and 13.25 mg FB/kg bw diet. Apart from the effects on the liver and kidney, a wide variety of
parameters, including cholesterol and creatine kinase, were also adversely affected. Several blood
parameters, including white and red blood cells, also signiﬁcantly decreased in the treated animals.
The serum sphinganine level and the sphingosine/sphinganine ratio, monitored toward the end of
the experiment, signiﬁcantly increased in both the low-dose and high-dose animals. The present
study provides important information about the diversity of lesions induced by culture material of F.
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concentrations during a pilot experiment to
avoid excessive toxicity (Table 1). The control
diet contained 0.5% autoclaved corn meal.
All diets were prepared in bulk (approxi-
mately 9.5 kg) and stored at 4°C and from
1992 they were routinely analyzed for aﬂatox-
ins and FB mycotoxins. The mixed diet was
prepared as a porridge after which vitamins
D3 (200 I.U.) and C (40 mg) were added
before feeding. The estimated energy and
nutrients supplied per vervet monkey per day
have been calculated and published in detail
elsewhere (11). The diet has been used to sus-
tain successful in-house breeding over several
generations with satisfactory development of
the offspring (12). The diet was supple-
mented further with 35.4 ± 4.1 g of whole-
wheat brown bread and a slice of apple (70.5
± 6.6 g) in the afternoon. Feed wastage was
monitored starting 4 years after the experi-
ment began. This was accomplished by first
weighing the dry and wet food as well as the
wet wastage collected from underneath the
cage. The dry wastage was extrapolated from
the wet:dry ratio of the food. Housing the
vervet monkeys in pairs after 5 years circum-
vented abnormal social behavior caused by
solitary conﬁnement. They also had access to
large exercise cages for 24 hr/week. 
One vervet monkey (female 681) of
Group 1 was used in a pilot study (approxi-
mately 3 months) to evaluate early signs of
toxicity from ingestion of culture material. As
the experiment progressed, the level of the
culture material incorporated in the diet was
altered accordingly (Table 1) to avoid exces-
sive toxicity. At that stage (1984/1985) the
FB mycotoxins had not been characterized,
and detailed chemical analyses of the diet and
culture material became possible only about
8 years after the experiment began (1991/
1992). Subsamples of the different fungal cul-
ture batches used during the course of the
experiment were retained and subsequently
analyzed for fumonisins in order to calculate
exposure levels. The different culture batches
were prepared according to standardized pro-
cedures using autoclaved yellow corn kernels
inoculated with single-conidial isolates of
F. verticillioides strain MRC 826 and were
incubated at 25°C for 2 weeks and then for 2
weeks at 15°C (8). Three different culture
batches designated batch B (BB), batch 55
(B55), and batch 57 (B57) were used during
the experiment. Batch BB was freeze dried;
B55 and B57 were oven-dried at 45–50°C.
The dry fungal cultures were ground to a ﬁne
meal and stored in airtight containers at 4°C. 
Clinical Monitoring
Appetite and habitus were observed daily;
body weights, heart rates, and respiration
rates were recorded at monthly intervals.
Blood samples for measurement of clinical
biochemical parameters were collected every 2
months throughout the experiment. These
parameters included aspartate transaminase
(AST), alanine transaminase (ALT), lactate
dehydrogenase (LDH), gamma glutamyl-
transferase (GGT), alkaline phosphatase
(ALP), conjugated, unconjugated, and total
bilirubin, glucose, urea, creatinine, sodium,
potassium, chloride, calcium, phosphorous,
and magnesium. These parameters reflect
liver, kidney, muscle, respiratory, intestinal,
and bone functions. Full and differential
counts of venous blood, collected in potas-
sium EDTA tubes, were obtained with a
Technicon H 6010 C cytochemical flow
through cell counter (Beckman/Coulter,
Cape Town, South Africa). Plasma lipids and
lipoproteins were analyzed at the time the
final liver biopsies were taken and when the
animals were sacriﬁced. 
Urinary creatinine clearance was moni-
tored when increased serum urea and creati-
nine became evident. A 24-hr urine sample of
each vervet was collected into a plastic con-
tainer with the aid of a stainless steel funnel
(13). The funnels drained the entire cage
ﬂoor and a strainer prevented contamination
with feces. Clearance of creatinine from the
serum was expressed as milliliters per
kilogram of body weight per minute. 
Disruption of Sphingolipid Metabolism 
It has been demonstrated in a variety of ani-
mal species that exposure to fumonisin
mycotoxins altered sphingolipid metabolism
and that FB1 and FB2 inhibit the enzyme
ceramide synthase in the sphingolipid
biosynthetic pathway (14). At the cellular
level this leads to an accumulation of sphin-
ganine, which is then manifested in changes
in the circulating levels of this base. During
the course of the experiment, serum levels of
the sphingoid bases sphingosine and sphin-
ganine (and hence their ratio) were moni-
tored over 60 weeks from January 1994 to
March 1995 (15). By this time, the experi-
mental groups (controls, low-dose and high-
dose groups) consisted of two females each.
Serum samples were drawn at regular inter-
vals during this period to yield 10 sets of
results. In addition, 24-hr urine samples
were collected at the same time as the last
two blood samples.
Table 1. Summary of the duration, dietary level, and daily intake proﬁles of different F. verticillioides MRC 826 culture batches used during the chronic feeding study in vervet
monkeys.a
Feeding regimens
No. of  FCMb Commenced Termination Duration FMC  intake
Group vervet (sex) (MRC 826) (%)  (dd/mm/yy) (dd/mm/yy) (days) (mg/kg bw/day) Terminated
Group 1 681(F) BB 5 13/12/84 03/01/85 21 705.8 30/06/87
High dose BB 1 04/01/85 18/01/85 14 141.2
(trial) BB 0.25 19/01/85 29/01/86 375 35.3
B55 0.50 30/01/86 31/03/87 425 70.6
Group 1 688 (F) BB 1 14/03/85 23/04/85 40 141.40 03/11/92
High dose 702 (M) BB 0.25 24/04/85 29/01/86 280 35.30 30/08/89
705 (M) BB 0.50 30/01/86 31/03/87 425 70.60 24/07/92
709 (F) B55 0.50 01/04/87 24/10/88 572 70.60 14/09/95
712 (F) B57 0.50 25/10/88 05/06/91 953 72.8 ± 17.9c 11/11/98
B57 1 06/09/91 11/11/98 2623 151.0 ± 36.8c
Group 2 696 (M) BB 0.25 14/03/85 23/04/85 40 34.0 14/01/94
Low dose 700 (M) BB 0.1 24/04/85 29/01/86 280 14.0 30/10/92
710 (F) BB 0.25 30/01/86 31/03/87 425 34.0 30/07/97
711 (F) B55 0.25 01/04/87 24/10/88 572 34.0 11/11/98
B57 0.25 25/10/88 05/06/91 953 35.2 ± 8.2c
B57 0.5 06/09/91 11/11/98 2623 73.6 ± 17.4c
Group 3 707 (F) Corn meal  0.5% 14/03/85 11/11/98 4993 84.5 ± 15.7c 11/11/98
Control 708 (F) Corn meal  0.5% 14/03/85 11/11/98 4993 84.5 ± 15.7c 11/11/98
aValues are means ± SD of at least 20 determinations per group of the surviving vervets. bTotal fumonisin concentration: MRC 826 BB = 5.31 mg FB/kg, MRC 826 B55 = 2.61 mg FB/kg, and MRC 826 B57 =
3.43 mg FB/kg. cCalculated from feed intake data monitored 3–6 times per year from 1989.
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Biopsy and Necropsy Procedures
The toxic effects of the different feeding regi-
mens were evaluated in liver biopsies taken at
different time intervals during the course of
the experiment. Subsequent investigations
regarding histopathologic changes in the liver
and kidneys of the animals terminated during
the experiment and those sacriﬁced at the end
of the experiment are currently in progress
and will be reported elsewhere. Initial biopsies
were taken on alternative monkeys of each
group on days 2 and 6 of the experiment, and
all individuals were subjected to biopsies at
180, 300, 520, 890, and 1,631 days after
commencement. Wedge liver biopsies were
taken by laparotomy under halothane general
anesthesia. For the histopathologic evaluation
of these biopsies, we used different staining
procedures, including orcin stain to detect bile
acids, cholesterol, and copper in hepatocytes;
standard hematoxylyn and eosin; periodic
acid–Schiff; and reticulin stains (10,11). 
Necropsy procedures in monkeys that
were terminated in extremis and at the end of
the experiment were performed after perfu-
sion fixation under surgical anesthesia. For
this ﬁxation, 4% buffered formalin (pH 7.2)
was perfused into the left ventricle at physio-
logic pressure (100 mm Hg) and ﬂow. Before
the perfusion, blood samples and fresh biop-
sies were collected from the liver and kidneys
for electron microscopy and biochemical
analyses. Cutting the femoral and jugular
veins as well as cutting deeply into the kid-
neys and liver ensured free flow of fixative.
Immersion of the organs in the buffered for-
malin, at which time the organ weights were
recorded, completed ﬁxation. 
Data Analysis
All statistical analyses and graphical summaries
were performed with the Number Cruncher
Statistical System (NCSS 2000), Statistical
System for Windows (16). The correlation
coefficients reported are the partial coeffi-
cients—the correlation between two variables,
with the effect of other possible confounders
excluded. The p values reported are the partial
values obtained from the multiple regression
analyses—the relationship between the depen-
dent and the independent variables after the
effect of the other independent variables has
been taken into account. The plots used the
spline smoother of the scatterplot option of the
program to draw the curves.
Results
Clinical Observations, Biopsies,
Necropsies, and Termination
The biopsies, which were taken at stipulated
time points, resulted in the death of one
female. The histopathologic evaluations of
these biopsies have been reported elsewhere
and suggested an active chronic toxic hepati-
tis (10) at a very early stage, whereas mild
portal-to-portal ﬁbrosis was reported in some
animals of the high-dose and low-dose groups
(11). Clinical observations indicated that the
females were in better condition than the
males. A number of vervet monkeys of the
low-dose and high-dose groups were termi-
nated during the course of the experiment
because of general poor health (Table 2).
These conditions of cachexia include ataxia,
poor food consumption, and weight loss. The
experiment was terminated 4,990 days after
commencement. At that stage the two con-
trols (females 707 and 708) and only one
each of the low-dose (female 711) and high-
dose (female 712) groups survived. The livers
of all the animals killed during treatment and
at termination showed signs of chronic toxic
hepatosis. Some animals (females 711 and
712) showed patchy atheromatous plaques in
the aorta. One animal (male 702) died from
brain hemorrhages with lesions in the cerebel-
lum, midbrain, and the right cortex. The kid-
neys were also affected, although some
animals, such as male 702, showed no speciﬁc
lesions. In one of the animals (male 705) ter-
minated after 2,689 days of treatment, only
microscopic cytoplasmic vacuolization of
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Table 2. Clinical symptoms and lesions observed at different times during the experiment as well as the major macroscopic changes noticed at termination.a
Dosage Days  after
Number Sex group commencement Symptoms and/or lesions Necropsy (macroscopic observations)
681 F H 929 Hemorrhage in abdomen (terminated) Pale liver with irregular surface
688 F H 2,791 Alopecia on trunk and thighs Fibrotic, atrophic liver (chronic toxic hepatosis)
702 M H 1,630 Cachexic, ataxic, difﬁculty in handling  Hemorrhages of about 1 cm in grey matter of midbrain; most recent and largest 
and eating food lesions found in the cerebellum, midbrain, and right cortex of the midbrain
705 M H 2,689 Focal hemorrhages in the skin Necrosis of the distal and proximal rectum; ﬁbrotic liver (chronic toxic hepatosis); 
hard kidneys with streaks of blood from the corticomedullary junction
709 F H 2,497  Weight loss, yellow discoloration of  Fibrotic, atrophic liver (chronic toxic hepatosis)
the periorbital skin, blood in feces
3,836 Yellow discoloration of the skin
712 F H 4,990 Termination of experiment Liver atrophic accentuated lobulation (chronic toxic hepatosis); multifocal to 
conﬂuent atheromatous plaques throughout the aorta
696 M L 2,414  Torsion of the colon Small, ﬁbrotic liver (chronic toxic hepatosis); colon and stomach contained 
3,228 Torsion of the colon hemorrhagic ulcers
700  M L 896  Mild subcutaneous hemorrhage in the  Fibrotic liver (chronic toxic hepatosis); hemorrhagic diasthesis; mild icterus
groin area
1,762 Erythema on right thigh and left abdomen
2,723  Mild alopecia on left arm, blood in feces
2,747 Vomition, reluctant to move
710 F L 2,650  Starring coat Hard ﬁbrotic liver (chronic toxic hepatosis); kidneys showed petechial hemor-
2,738  Blood in feces rhages in cortex; enlarged lymph nodes and inﬂamed mesenteries
2,812  Yellowish discoloration of skin
4,521 Cachexia, vomition
711  F L 896  Focal hemorrhages in the skin of abdomen  Atrophic liver with nodular appearance and accentuated lobulation and cobble-
and left leg (disappeared after 30 days) stone effect; chronic toxic hepatosis; a few patchy atheromatous plaques in 
the aorta
3,707  Consistently poor feed consumption
4,990 Terminated experiment
707  F Controls 4,990  Termination of experiment  No clinical signs
708  F Controls 4,990  Termination of experiment  No clinical signs
aAll cases were terminated in extremis except females 707, 708, 711, and 712.
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epithelial cells of convoluted tubules was
present. The other cases that were terminated
demonstrated mild to severe cortical nephro-
sis manifested as toxic atrophy of the epithelia
of the convoluted tubules and probably the
glomeruli. No acute or chronic inﬂammation
was present. Final body and organ weights
(Table 3) indicated that the relative liver
weights of the high-dose group appeared to
be slightly lower than that of the low-dose
group, but the low number of animals and
differences in sex meant that statistical analy-
ses could not be performed. However, despite
the toxic effects encountered in the liver and
kidneys, multiple regression analyses showed
a positive correlation (r = 0.47; p < 0.0001) of
fungal culture material (FCM) intake and
body weight. It should be noted that the
higher dose levels were administered from
1992 onward during the stage of the experi-
ment where the vervets had established their
adult weight. The loss in body weight in
those vervet monkeys sacrificed in extremis
was encountered only a few months before
termination. Therefore the dietary levels of
FCM used apparently did not affect the nor-
mal body weight gain of the vervet monkeys
with age.
Feed and Fumonisin Intake Parameters
Feed intake proﬁles were conducted in detail
about 4 years after commencement of the
experiment. Discovery of the fumonisins (7)
and the development of the relevant analytic
methodology (17) resulted in routine analyses
of the maintenance diet for the fumonisins,
including retrospective analyses of the differ-
ent culture batches used. Given these data,
the FB intake during the earlier part of the
experiment could be estimated fairly accu-
rately (Table 4). However, several variables
complicate the calculation of accurate expo-
sure data, expressed as mean intake per kilo-
gram body weight per day for the duration of
the experiment. These variables included the
varying levels of the fungal material in the
diet as well as the use of different culture
batches (Table 1) containing different levels
of total FB (FB1, FB2, and FB3), namely
MRC 826 BB (5.38 mg FB/kg), MRC 826
B55 (2.61 mg/FB/kg), and MRC BB57 (3.73
mg FB/kg). During the last 8 years only one
culture batch (BB57) was used, although the
dietary level of the culture material was raised
from 0.25 to 0.5% in the low-dose group and
from 0.5 to 1% in the high-dose group. The
mean total FB intake of the vervet monkeys
in the different groups, as a function of the
various cultures and dietary levels used during
the experimental period, is illustrated in
Figure 1. 
Clinical Pathology
For the purpose of this article, the parameters
used to assess liver function are presented sep-
arately from those associated with kidney
function.
Serum enzymes associated with liver func-
tion. General patterns. Multiple regression
analyses of the serum enzyme indicators asso-
ciated with hepatocellular damage (AST,
ALT, LDH, and GGT) indicated that males
Table 3. Comparison of body and organ weights of the vervet monkeys fed high and low doses of F. verticillioides culture material for different time periods.
Terminated Body weight
Vervet (dd/mm/yy) (kg) Liver (g) % Left kidney (g) % Right kidney (g) % Total kidney (g) % Heart (g)  % Brain (g) %
High dose
681 (F) 30/06/87 3.67 55 1.50 7.564 0.21 7.352 0.20 14.92 0.41 20.5 0.56 71 1.93
702 (M) 30/08/89 4.29 64.4 1.50 6.84 0.16 7.45 0.17 14.29 0.33 24.7 0.58 69.82 1.63
705 (M) 24/07/92 4.79 69.2 1.44 8.35 0.17 8.31 0.17 16.66 0.35 36 0.75 63.9 1.33
688 (F) 03/11/92 2.70 53.5 1.98 8.885 0.33 9.884 0.37 18.77 0.70 16.9 0.63 62 2.30
709 (F) 14/09/95 3.38 43.62 1.29 8.91 0.26 9.7 0.29 18.61 0.55 21.59 0.64 63.3 1.87
712 (F) 11/11/98 5.71 79.49 1.39 8.94 0.16 8.11 0.14 17.05 0.30 49.23 0.86 71.96 1.26
Low dose
700 (M) 30/10/92 4.94 69.5 1.41 10.2 0.21 9.9 0.20 20.10 0.41 28.2 0.57 65.5 1.33
696 (M) 14/01/94 5.71 86.96 1.52 10.66 0.19 14.95 0.26 25.61 0.45 39.78 0.70 66.4 1.16
710 (F) 30/07/97 3.24 82.1 2.53 7.66 0.24 7.37 0.23 15.03 0.46 22 0.68 68 2.10
711 (F) 11/11/98 4.48 75.78 1.69 9.32 0.21 9.28 0.21 18.60 0.42 31.7 0.71 70.54 1.57
Controls
707 (F) 11/11/98 3.23 70.1 2.17 ND ND ND ND 59.88 1.85
708 (F) 11/11/98 3.69 66.56 1.80 8.43 0.23 8.79 0.24 17.22 0.47 23.9 0.65 57.57 1.56
ND, not determined.
Table 4. Summary of the body weight in relation to the average feed, F. verticillioides culture material, and the calculated and estimated fumonisin intake during the experiment. 
Body weight (kg) Average  Total 
Duration Maximum Final feed intake Mean FCM/ FB/kg bw/day (mg) FB (mg)
Vervet (days) Initial (dd/mm/yy) (dd/mm/yy) (g/kg bw/day) kg bw/day (mg) Estimateda Calculatedb estimated
High dose
681 (F) 929 2.57 –  3.07 (30/06/87) 14.12 ± 2.14 80.03 ± 44.59 0.38 ± 0.27c – 330.4
688 (F) 2,791 2.42 4.05 (24/07/91) 2.70 (03/11/92) 15.45 ± 1.79 90.4 ± 40.9 0.39 ± 0.22 861.2
702 (M) 1,630 1.75 4.45 (14/02/89) 4.29 (30/08/89) 14.12 ± 2.14 77.6 ± 38.7 0.36 ± 0.24 – 431.6
705 (M) 2,689 1.76 5.20 (15/03/91) 4.79 (24/07/92) 15.45 ± 1.79 89.5 ± 44.7 0.39 ± 0.22 – 832.7
709 (F) 3,836 1.50 –  3.38 (14/09/95) 16.10 ± 1.55 98.5 ± 55.5 0.42 ± 0.25 – 1714.6
712 (F) 4,990 1.50 3.92 (27/04/95) 3.70 (11/11/98) 16.11 ± 1.50 80.1 ± 35.56 0.35 ± 0.21 0.49 ± 0.20 2147.2
Low dose
696 (M) 3,228 2.09 6.03 (26/08/93) 5.71 (14/01/94) 14.91 ± 1.21 36.89 ± 18.69 0.15 ± 0.07 – 1304.08
700 (M) 2,747 2.25 6.03 (15/01/91) 4.94 (30/10/92) 14.23 ± 1.46 36.89 ± 18.69 0.15 ± 0.07 – 1022.98
710 (F) 4,527 1.61 3.65 (24/07/91) 3.24 (30/07/97) 15.1 ± 1.08 37.78 ± 20.68 0.16 ± 0.08 – 1846.20
711 (F) 4,990 1.62  –  4.48 (11/11/98) 15.1 ± 1.08 37.78 ± 20.68 0.16 ± 0.08 0.17 ± 0.09 2037.97
Control
707 (F) 4,990 1.58 3.38 (25/06/96) 3.23 (10/11/98) 17.74 ± 1.67 88.72 ± 8.34 0.01 ± 0.006 –
708 (F) 4,990 1.45 3.80 (05/08/98) 3.69 (10/11/98) 17.74 ± 1.67 88.72 ± 8.34 0.01 ± 0.006 0.01 ± 0.01 48.94
aEstimated from the feed intake proﬁles. Levels that were estimated before 1989 were based on the feed intake proﬁles that were measured during 1989. bDosage was calculated from routine analyses of
the stock feed samples since 1992. cExposure of female 681 to 5% for 40 days was not included in calculating the average fumonisin intake proﬁle. The average intake during that period was 3.79 mg
FB/kg/day. 
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showed higher levels of LDH and GGT and
females had higher levels of ALT; there was no
difference between them with respect to AST
serum levels (Table 5; Figure 2). AST and
GGT increased signiﬁcantly as a function of
time, whereas ALT and LDH decreased.
Females exhibited a higher cholesterol level;
males had higher levels of total bilirubin.
Overall, the total bilirubin increased as a func-
tion of time, but cholesterol was not affected.
All the markers mentioned above were signiﬁ-
cantly (p < 0.0001) positively correlated with
the levels of the FCM and hence the levels of
total FB. Glucose and ALP, serum markers
not necessarily associated with liver function,
showed a negative (r = –0.48; p < 0.0001) and
a positive (r = 0.40; p < 0.0001) correlation,
respectively, with FCM (Table 5; Figure 2).
Glucose tended to increase with time, but
there were no differences between males and
females. ALP decreased signiﬁcantly with age,
with males exhibiting higher levels than
females. Creatine kinase, measured only from
1991 onward, increased with time and was
also positively correlated (r = 0.57; p <
0.0001) with FCM (Table 5). 
Dose–response effects. When considering
the above results, two critical time periods
exist (Figure 1): when the FB intake was
reduced as a result of the use of different cul-
ture batches between 1986 and 1990; and
when the FB intake profiles were increased
due to a doubling of the dietary level of the
culture material between 1991 and 1992. 
During 1987 a different culture batch of
the fungus (B55) replaced the original batch
(BB), decreasing the FB intake proﬁle. Both
culture batches were included at a dietary
level of 0.5% (high dose) and 0.25% (low
dose). The total FB concentrations were 5.38
mg/kg and 2.61 mg/kg culture material for
BB and B55, respectively. The FB intake pro-
files decreased from 0.18 to 0.11 mg/kg
bw/day in the low-dose group and from 0.38
to 0.18 mg/kg bw/day in the high-dose
group. Toward the end of 1988 another cul-
ture batch, B57 (3.73 mg FB/kg), was intro-
duced into the experiment and slightly
increased the FB intake profiles to 0.13 ±
0.03 and 0.29 ± 0.04 mg/kg bw/day during
1989 and 1990 for the low-dose and high-
dose groups, respectively (Figure 1). 
A downward trend occurred in the liver
function enzymes, AST and ALT, during the
1986–1988/1989 period in the high-dose
group (Figure 2). In the low-dose group, the
activities of the enzymes were very similar to
those of the control females. No differences
were observed between the dosage groups
with respect to the total bilirubin and blood
glucose levels. However, serum cholesterol
levels showed a downward trend in the high-
dose group similar to that mentioned for AST
and ALT. The levels of ALP tended to
decrease with time in the controls and the
low-dose group, but this decrease was
markedly delayed in the high-dose group.
When the dietary level of the culture material
(B57) was increased 2-fold during the end of
1991, AST, ALT, and cholesterol levels
increased markedly during 1992 in both the
high-dose and low-dose groups compared to
the control group. There were no clear differ-
ences between the low-dose and high-dose
groups toward the end of the experiment,
although a higher trend was observed initially
in AST and cholesterol levels (Figure 2). The
same holds for total serum bilirubin and
blood glucose, which, respectively, increased
and decreased markedly in the high-dose
group. The low-dose group also showed mar-
ginal effects with levels just above those of the
control females. Creatine kinase, monitored
from 1991 onward, also showed a marked
dose–response effect with no clear-cut differ-
ence between the high-dose and low-dose
groups (data not shown).
Serum enzymes associated with kidney
function. General patterns. Serum urea (r =
0.41; p < 0.0001) and creatinine (r = 0.74;
p < 0.0001) were positively correlated with
the dietary levels of FCM and increased sig-
nificantly compared to the controls (Table
4). In both cases males exhibited higher lev-
els than females; urea decreased and creati-
nine increased as a function of time.
Multiple regression analyses indicated that
FCM was negatively correlated (r = –0.47;
p < 0.0001) with a decrease in creatinine
clearance. The latter also tended to decrease
as a function of time; males had lower
clearance values than females. 
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Figure 1. Daily fumonisin intake data of the low-dose (dotted line) and high-dose (solid line) groups of vervet mon-
keys as a function of the different culture batches of Fusarium verticillioides strain MRC 826 (BB, B55, B57) used dur-
ing the course of the experiment. 
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Table 5. Partial correlation coefﬁcients from multiple regression analyses of different serum parameters associated
with liver and kidney function. The correlation factor for FCM was corrected for age and sex.
Sex Age FCM
Dependent ra p Levelb rp Levelb rp Levelb R2
Serum
Urea (log) –0.11 0.0035 –0.27 < 0.0001 0.41 < 0.0001 0.2191
Creatinine (log) –0.40 < 0.0001 0.28 < 0.0001 0.56 < 0.0001 0.3629
Glucose (log) 0.08 0.0744 0.21 < 0.0001 –0.48 < 0.0001 0.2624
Cholesterol (log) 0.17 < 0.0001 –0.05 0.1177 0.40 < 0.0001 0.1856
Total bilirubin (log) –0.20 < 0.0001 0.27 < 0.0001 0.37 < 0.0001 0.2599
AST (log) 0.00 0.9597 –0.13 0.0001 0.67 < 0.0001 0.4545
ALT (log) 0.24 < 0.0001 –0.19 < 0.0001 0.42 < 0.0001 0.2067
LDH (log) 0.02 0.6535 –0.28 < 0.0001 0.47 < 0.0001 0.2366
GGT (log) –0.13 0.0002 0.10 0.0055 0.53 < 0.0001 0.3296
ALP (log) 0.14 < 0.0001 –0.72 < 0.0001 0.40 < 0.0001 0.5207
Creatinine kinase (log) 0.00 0.9742 0.29 < 0.0001 0.57 < 0.0001 0.3536
Urine
Serum creatinine (log)c –0.0125 0.0691 –0.15 0.0371 0.74 < 0.0001 0.5443
Creatinine clearance –0.0109 0.0308 –0.22 0.0018 –0.47 < 0.0001 0.2541
Urine (log) –0.0332 0.8618 0.02 0.7994 0.07 0.3917 0.0056
aA positive correlation indicates females higher than males. bSigniﬁcance level (on multiple regression analysis). cCreatinine clear-
ance was measured from 1991.
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Dose–response effects. As discussed for
the liver function enzymes, two time points
were selected: between 1986 and 1988 and
between 1991 and 1993 time periods. From
1986 to 1988, no decreases in the serum urea
and creatinine levels were noticed in either of
the treated groups (Figure 3). During the
1991–1993 dose increase, the serum urea
level of the high dose slowly increased until
1995, after which there was a clear distinction
between the high-dose and the low-dose and
control groups. Creatinine clearance was
assessed only from 1992 on, and both the
high-dose and low-dose groups showed a
reduced capacity (Figure 3). However, the
low-dose group tended to revert to control
values after about 4 years. The high-dose ani-
mals showed a consistently lower creatinine
clearance compared to the control females,
and the reduced creatinine clearance capacity
relates well with the increased urea and creati-
nine levels in the serum.
Differential blood counts. Differential
blood counts were performed from 1991
onward. The white blood cell (WBC) counts
were negatively correlated (r = –0.49;
p < 0.0001) with the FCM levels in the diet
Figure 2. Multiple regression analyses of selected serum parameters associated with liver function and other important serum components during the experimental period. Hi,
high dose; Lo, low dose; Ctl, control; Tot_Bilirubin, total bilirubin. 
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(Table 6). In general WBC counts tended to
decrease with time, although females exhibited
higher WBCs. With respect to the relative
contribution to the WBC count, eosinophils,
monocytes, and basophils increased as a result
of the FCM dietary treatment; the lymphosites
decreased. These parameters were also age
dependent; neutrophils and eosinophils tended
to decrease and monoscytes increased as a
function of time. Except for the monocytes,
which were higher in males, there were no sex
differences in the other WBC components.
From the spline smooth (Figure 4), both the
low-dose and high-dose groups showed a
marked decrease in the WBC count, which
tended to approximate values of the controls
toward the end of the experiment. 
The red blood cell (RBC) count was
lower in females (r = –0.48; p < 0.0001),
increased with age (r = 0.11; p < 0.04), and
was negatively correlated (r = –0.45;
p < 0.0001) with FCM dietary levels (Table
6). A similar effect was noticed for hemoglo-
bin (Hb) and the hematocrit (HCT), except
that both parameters also increased with age.
The red cell distribution width (RDW) posi-
tively correlated (r = 0.18; p < 0.0001) with
FCM treatment despite the fact that it gener-
ally decreased with age. The graphical plots
(spline smooth) indicated that these parame-
ters were affected in both the high-dose and
low-dose groups, whereas the low-dose group
tended to approximate the control values
toward the end of the experiment (Figure 4).
The mean corpuscular volume (MCV), the
mean corpuscular hemoglobin (MCH), and
the mean corpuscular hemoglobin concentra-
tion (MCHC) were not affected by FCM,
whereas the MCV and MCHC were higher
in males and tended to increase with age.
Blood platelet (PL) counts and the mean
platelet volume (MPV) significantly
(p < 0.0001) decreased as a result of FCM
treatment despite the fact that PL decreased
and MPV increased, respectively, as a function
of age. Females had higher platelet counts than
males, whereas the MPV tended to be lower in
females. The spline smooth graphical plot
showed some lowering effects on PL by both
the low-dose and high-dose groups throughout
the experiment (Figure 4). The MPV clearly
showed a decrease in the high-dose group; the
low-dose group tended to exhibit similar values
toward the end of the experiment.
Two males, one of the high-dose group
(male 705) and one of the low-dose group
(male 700), were terminated during the sec-
ond year after the dose increase, followed by
the last male (low-dose; male 696) during the
third year. One high-dose female (female 688)
died within 2 years of the dosage increase. 
Alteration of Sphingolipid Metabolism
During the monitoring period for sphin-
golipid basis, mean sphingosine levels were
not signiﬁcantly different between any of the
experimental groups, whereas sphinganine
levels were signiﬁcantly (p < 0.05) elevated in
both the low-dose and high-dose groups con-
suming the FCM (15) as compared to the
controls. However, although the high-dose
group had a numerically higher sphinganine
concentration, the individual variability
observed both between and within vervet
monkeys in each group caused the 95% con-
ﬁdence limits to be wide. Consequently, this
difference between the low-dose and high-
dose groups was not statistically significant
(p > 0.05). During this period, the sphinga-
nine/sphingosine (Sa/So) ratio in the serum
increased from 0.43 in the controls to 1.72 in
the low-dose and 2.57 in the high-dose
groups, with the latter two means signifi-
cantly elevated over the control (p < 0.05) but
not signiﬁcantly different from each other. 
During the monitoring period, only a few
samples of urine were analyzed. The sphin-
golipid base levels in urine have been linked
to its cellular content because of the presence
of exfoliated cells (18); hence, the levels of the
individual bases will vary accordingly, making
the ratio potentially a more reliable measure
of disruption in sphingolipid metabolism.
Although the results indicated a numeric
increase in the Sa/So ratio for the two experi-
mental groups, once again there was consider-
able variation and the values were not
statistically signiﬁcantly different.
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Figure 3. Graphical illustration of the effect of the low and high dose of FCM on clinical parameters associated with
kidney function. Hi, high dose; Lo, low dose; Ctl, control; Ser_Creatinine, serum creatinine; Creat_Clear, creatinine
clearance. Creatinine clearance was measured only from 1992 and onward. Serum creatinine measurements were
performed during the course of the experiment as well as during the creatinine clearance determinations.
Table 6. Partial correlation coefﬁcients from multiple regression analyses of blood parameters measured as a func-
tion of sex, year, and FCM. The correlation factor for FCM was corrected for age and sex.
Sex Age FCM
Dependent ra p Levelb rp Levelb rp Levelb R2
Blood parameters
WBC (log) 0.28 < 0.0001 –0.23 < 0.0001 –0.49 < 0.0001 0.2878
Lymphocytes –0.03 0.5937 0.06 0.2857 –0.11 0.0435 0.0200
Neutrophils (log) 0.08 0.1941 –0.17 0.0036 –0.08 0.1593 0.0333
Eosinophils (log) –0.02 0.7484 –0.14 0.0243 0.14 0.0229 0.0469
Basophils (log) –0.10 0.1213 –0.06 0.3057 0.28 < 0.0001 0.0874
Monocytes –0.14 0.0216 0.38 < 0.0001 0.44 < 0.0001 0.2725
RBC –0.48 < 0.0001 0.11 0.0446 –0.45 < 0.0001 0.3603
Hemoglobin –0.61 < 0.0001 0.20 0.0003 –0.45 < 0.0001 0.4616
RDW (log) –0.02 0.6688 –0.43 < 0.0001 0.18 < 0.0001 0.2443
MCV (log) –0.20 0.0003 0.13 0.0232 0.08 0.1606 0.0497
MCH –0.22 < 0.0001 0.13 0.0216 0.09 0.1224 0.0569
MCHC –0.05 0.3295 0.02 0.6751 0.04 0.5027 0.0045
PL (log) 0.53 < 0.0001 –0.40 < 0.0001 –0.33 < 0.0001 0.3584
MPV –0.13 0.0234 0.17 0.0029 –0.35 < 0.0001 0.1631
aA positive correlation indicates females higher than males. bSigniﬁcance level (on multiple regression analysis). 
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Histopathology
The liver biopsies, taken at regular intervals
up to the middle of 1990, revealed lesions
that are characteristic of a chronic toxic
hepatosis and that varied from subacute to
acute effects in the vervet monkeys receiving
the high dose of the culture material (10,11).
These changes included perilobular fibrosis,
nodular hyperplasia, apoptosis, distortion of
reticulin staining pattern, and mild to scant
bile duct proliferation, which distorted the
normal architecture of the liver. Hepatocyte
nodules were uneven in size and showed
increased mitosis, uneven nuclear size, and
single-cell necrosis (apoptosis). Bi-nucleated
cells, fatty changes, and in some cases (female
681) influx of inflammatory cells were
noticed randomly throughout the liver.
Similar changes were observed in the livers of
the vervet monkeys terminated during the
experiment. The livers of terminated animals
were markedly smaller, with portal-to-portal
fibrosis and nodular hyperplasia as constant
features (Table 5). In the low-dose group no
specific changes were apparent except in
female 710, where disseminated foci of hepa-
tocellular necrosis and inﬂammatory response
occurred with a scant distortion of the reticu-
lar pattern. One of the control females (708)
also presented with focally disseminated,
mild, eosinophilic hepatitis, with no speciﬁc
toxic lesions of distortion of the lobular struc-
ture except in the areas with hepatitis. This
lesion was similar to that observed in the low-
dose female 710 and, to some extent, in the
high-dose female 688 and was ascribed to
chronic parasitic hepatitis.
Discussion
Previous reports on the effects of culture
material of F. verticillioides MRC 826 on
vervet monkeys used in the same long-term
experiment (10,11) indicated that the liver is
an important target organ. The levels of major
serum enzymes used as markers for liver dam-
age (ALT, AST, GGT, and LDH) were ele-
vated in the high-dose and low-dose groups
depending on the dietary level of FCM.
Jaskiewicz et al. (10) reported increased levels
of AST, ALT, and LDH in vervet monkeys
within the ﬁrst few days in a pilot trial with
culture material of MRC 826. The high-dose
group that received 1% showed a marked
increase within 14 days and a decrease within
2–3 weeks after the dose was lowered to
0.25%. The increase in hepatocellular enzyme
activity in the low-dose group was far slower
and first appeared 6–7 weeks after the treat-
ment commenced. Increases in total bilirubin
and cholesterol paralleled these early changes
in liver enzyme activities. These ﬁndings were
conﬁrmed with multiple regression analysis of
all the data as a function of the FCM dietary
levels used for the duration of the experiment.
The dose–response effects previously
described by Jaskiewicz et al. (10) were also
clearly illustrated over the period of decreased
FCM intake (1986–1988) and the period of
increased FCM intake (1991–1993).
However, detailed dose–response effects and
statistical evaluation of the data with respect
to the biochemical parameters measured are
complicated by the fact that low numbers of
animals were used in each group, both males
and females were used, and some of the vervet
monkeys from each group were terminated in
extremis during the course of the experiment.
Despite these complications and that fact that
some interindividual variations seem to exist
among vervet monkeys, the low-dose groups
exhibited levels of AST, ALT, LDH, and
GGT similar to those of the controls during
1988. During this treatment period, the total
FB level was at a minimum and it would
appear that at this exposure level (0.10 mg
FB/kg bw/day) very few changes are induced
in liver function enzymes. The same is true for
serum cholesterol, total bilirubin, glucose, and
ALP values, although some individual varia-
tion appears to occur. Some animals in the
high-dose group showed a marked decrease in
the levels of the serum enzymes and closely
resembled those of the controls. The mini-
mum dosage level of the high-dose group,
reached during 1988, was on the order of 0.18
mg FB/kg bw/day. 
Changes in the serum parameters, associ-
ated with an increase in the FCM level in the
diet, were monitored during 1991–1993. All
liver function serum enzymes showed a
marked increase from the 1991 background
level in the high-dose animals. The increased
dietary level of FCM represents an FB expo-
sure level from approximately 0.38 mg/kg
bw/day in 1991 to 0.64 mg/kg bw/day in
1992. Serum enzyme levels also increased in
the low-dose animals after an increase of the
FB intake from approximately 0.18 to 0.28
mg/kg bw/day. In some of the low-dose ani-
mals the serum enzyme levels equaled those of
the high-dose group. A threshold for liver
damage in vervet monkeys ranged between
Figure 4. Dose–response effects of FCM on selected blood parameters from 1991 to 1989. Hi, high dose; Lo, low
dose; Ctl, control. 
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0.10 mg FB/kg bw/day (low dose 1988) and
0.18 mg FB/kg bw/day (low dose 1991),
where most of the vervets exhibited baseline
values compared to the control females. In
general, it appears that males were more sensi-
tive than females because three males were ter-
minated within 2–3 years after the dietary level
of the culture material was doubled. Only one
high-dose female died during this period.
Histopathologic changes associated with
changes in liver enzyme activities have been
described in detail. These changes suggest a
chronic toxic hepatosis that simulates acute
viral hepatitis, with some similarities to the
effects induced by aﬂatoxins. Mild portal-to-
portal ﬁbrosis was also described by Fincham et
al. (11) in biopsy specimens of both the high-
dose and low-dose groups collected up to 1,631
days (middle 1989) after the experiment began.
These biopsies also indicated that consumption
of culture material of the fungus (high dose)
caused atherogenic plasma lipid profiles to
develop. These changes entailed elevations of
plasma low-density lipoprotein (LDL)-C and
apoprotein B strongly associated with acceler-
ated atherosclerosis in vervet monkeys. It was
suggested (11) that increased plasma cholesterol
could be related to changes at the hepatocyte
membrane leading to a reduced or impaired
internalization of LDL into the hepatocytes,
and hence the reduced clearance from the
plasma. The reduced receptor activity might be
caused by cytotoxicity induced by the FCM, an
aspect that was clearly indicated by the serum
enzyme proﬁles related to liver function. It was
suggested that the synthesis of cholesterol was
not affected, although in rats cholesterol accu-
mulates both in the plasma and the liver (19).
Plaque formation in the aorta of some of the
animals sacrificed (Table 3) is therefore of
interest in this regard. Additional studies must
be conducted to evaluate the role of FB on cho-
lesterol metabolism because it can effect
changes in lipid metabolism in rat liver at
different levels (19).
We also monitored the effects of the
1986–1988 and 1991–1992 changes in
dietary levels of FCM on renal function. The
low-dose group did not show any marked
changes in serum urea or creatinine during the
1986–1988 culture batch dietary change.
However, most of the high-dose animals
showed elevated levels and therefore did not
reﬂect the decrease in FB levels from 0.35 mg
FB/kg bw/day in 1986 to 0.18 mg/kg bw/day
in 1988. The 1991–1992 dosage increase
markedly increased the serum creatinine levels
in all high-dose vervet monkeys and in most
of the animals of the low-dose group. The
results of these two time points suggest that a
threshold for changes in these two renal para-
meters exists in the region of 0.18–0.2 mg
FB/kg bw/day as discussed for liver function.
Creatinine clearance was monitored only
1 year after the dosage increase and showed
markedly lower values during 1992 compared
to the controls. All females (both high-dose
and low-dose groups) showed a remarkable
recovery phase over the first 3 years, where-
after creatinine clearance decreased to values
similar to those of the control females.
Although creatinine clearance is widely inter-
preted as a measure of glomerular filtration
rate (GFR) and therefore renal function, the
serum creatinine levels can be affected by
many variables apart from glomerular filtra-
tion (20). These variables include the reab-
sorption and secretion of creatinine by renal
tubules, which could over- or underestimate
the GFR. In the present study, some nephro-
toxic effects were noticed in the proximal
tubular epithelium that could have decreased
the tubular excretion of creatinine and there-
fore reduced the urinary levels of creatinine
and indirectly affected the measured GFR. 
Of interest were changes in the level of
creatine kinase, which were markedly
increased in all the high-dose animals in a
dose-dependent manner. Monitoring total
creatine kinase activity, measurement nor-
mally reflects the muscle isoenzyme because
the heart and brain isoenzymes occur at far
lower levels (21). As discussed for creatine
kinase, care must be taken when interpreting
the various clinical biochemical serum para-
meters. Some of the parameters, such as LDH
and ALP, consist of many isoenzymes, each
associated with speciﬁc tissue compartments,
and electrophoretic enzyme characterization is
required for identiﬁcation (20). Bone origin of
ALP elevations is quite easy to distinguish
from hepatobiliary conditions in the absence
of increased levels of AST, ALT, and GGT.
AST and ALT have no specific isoenzymes,
but AST is quite widely distributed in skeletal
and cardiac muscle, liver, and erythrocytes.
GGT occurs mainly in the liver and kidneys,
but clinically it is conﬁned to liver conditions;
in small animals it roughly parallels ALT.
Increases in bilirubin can also result from
many abnormal physiologic conditions,
including liver failure and obstructive biliary
disease. Although Jaskiewicz et al. (10)
reported cholestasis in the high-dose group,
this could not be conﬁrmed in subsequently
biopsied animals that received decreased
dosage levels of the culture material. It would
appear that chronic liver injury was responsi-
ble for increased levels of total plasma biliru-
bin. As discussed for bilirubin, an increase in
plasma cholesterol could be related to a
number of causes, including diabetes mellitus,
liver or biliary disease, or a fatty meal (21). It
was suggested that in the absence of cholesta-
sis, a reduced uptake of LDL cholesterol,
caused by changes to the hepatocyte mem-
branes, could be an important reason for the
increased serum cholesterol (11). Of interest is
the ﬁnding of Fincham et al. (11) that culture
material caused atherogenic effects in the
high-dose vervet monkeys in this experiment.
This study provides interesting exposure
parameters to be considered regarding
dose–response effects of FB contaminated
feeds and/or foods. The no-observed-effect
level, with respect to the total fumonisin levels
in the corn culture material, for liver and kid-
ney damage in vervet monkeys can be esti-
mated at between 0.11 and 0.18 mg FB/kg
bw/day. This level is slightly below the values
proposed to effect natural outbreaks of ELEM
(0.6–2.1 mg/kg bw/day) (22). The probable
daily intake (PDI) calculated for humans con-
suming corn as the staple diet, such as in the
Transkei region of the Eastern Cape Province
of South Africa, is 0.36 and 0.047 mg FB/kg
bw/day when consuming “moldy” and
“healthy” corn, respectively (23). These PDI
values decreased considerably when calculated
for people consuming corn exported from
South Africa (0.002 mg FB/kg bw/day) or
from the United States (0.007 mg FB/kg
bw/day). Based on the FB-intake profiles of
the vervet monkeys of 0.11 to 0.18 mg FB/kg
bw/day and an average feed intake proﬁle of
16.0 ± 1.6 mg/kg bw/day, fumonisin contam-
ination levels of corn between 8.21 and 13.25
mg FB/kg diet can be calculated. These values
appear not to affect liver and kidney function
in the vervet monkey but were suggested to be
dangerous to horses, and 10-fold higher values
could induce pulmonary edema syndrome in
pigs (21). Changes in sphingolipid metabo-
lism, specifically in the sphinganine concen-
tration and the Sa/So ratio, were effected in
the serum and also to some extent in the urine
of the vervet monkeys at dietary levels of
0.29–0.64 mg FB/kg bw/day. These intake
levels represent, as calculated above, contami-
nation levels in corn of 21.7–47.8 mg FB/kg.
The vervet monkey appears to be a promising
model to study the use of the Sa/So ratio as a
biomarker to determine fumonisin exposure
in human populations. 
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